A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica

Checkpoint inhibitors are recent therapies against cancer, and their indications are currently undergoing rapid expansion. However, these treatments unleash immune activation that triggers potential autoimmune side-effects. Such cases are reported but remain rare and misdiagnosed. We report the case of a patient treated with pembrolizumab, who developed autoimmune haemolytic anaemia (AIHA) and polymyalgia rheumatica (PMR). Letter to the editor: Comments on ‘A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica’European Journal of CancerVol. 111PreviewWe read with interest the report by Robilliard et al. [1] of a pembrolizumab-induced immune-related adverse event (irAE). We applaud them for bringing attention to polymyalgia rheumatica (PMR) as a rheumatic irAE after immune checkpoint inhibitor therapy and would like to add some comments and conclusions. Full-Text PDF